When was Cabaletta Bio founded?

Cabaletta Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Cabaletta Bio located?

Cabaletta Bio is headquartered in Radnor, United States. It is registered at 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 United States.

Who is the current CEO of Cabaletta Bio?

Steven Nichtberger and Steven Nichtberger s of Cabaletta Bio.

How many employees does Cabaletta Bio have?

As of May 31, 2026, the latest employee count at Cabaletta Bio is 189.

Is Cabaletta Bio a funded company?

Cabaletta Bio is a funded company, having raised a total of $88.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 07, 2018.

When was the latest funding round of Cabaletta Bio?

Cabaletta Bio's latest funding was a $***** Series B round on Jan 03, 2019, with participation from 6 investors.

Where does Cabaletta Bio rank among its competitors?

Cabaletta Bio ranks 35th amongst 945 active competitors, of which 334 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Cabaletta Bio?

Cabaletta Bio's top competitors include BridgeBio, BeiGene and Alnylam. Among them, BridgeBio secured the most recent funding round in April, 2024.

Cabaletta Bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of CAAR T cells for B cell-mediated autoimmune diseases. The company has developed a technology based on CAR-T cell platform to produce selective CAAR T cells that would kill autoantibody-producing B cells.

Website: www.cabalettabio.com/
Social
Email ID: *****@cabalettabio.com
Phone Number: +1 **********
Registered Address: 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 United States

Key Metrics

Founded Year

2017

Location

Radnor, United States

Stage

Public

Total Funding

$88.3M in 2 rounds

Latest Funding Round

Series B, Jan 03, 2019, $*****

Investors

5AM Ventures & 6 more

Ranked

35^th among 945 active competitors

Employee Count

189 as on May 31, 2026

Similar Companies

BridgeBio & 1087 more

Exit Details

Public

View Cabaletta Bio's full profile

Cabaletta Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CABALETTA BIO, INC. CIN: 82-1685768 , United States, Active	May 02, 2017	-	60 (As on Dec 31, 2022)	-

Cabaletta Bio got listed on Oct 25, 2019.

Click here to take a look at Cabaletta Bio's IPO in detail

Cabaletta Bio has raised a total funding of $88.3M over 2 rounds. Its first funding round was on Dec 07, 2018. Its latest funding round was a Series B round on Jan 03, 2019 for $*****. 6 investors participated in its latest round. Cabaletta Bio has 7 institutional investors.

Here is the list of recent funding rounds of Cabaletta Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 03, 2019	8686807	Series B	4605224	3733375	9056508	4708485
Dec 07, 2018	3764402	Series A	6425707	6517054	5AM Ventures	Adage Capital Management & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Cabaletta Bio's funding rounds and investors

The founders of Cabaletta Bio are Aimee P, Steven Nichtberger, Steven Nichtberger and Michael Milone.

Here are the details of Cabaletta Bio's key team members:

Aimee P: Co-Founder of Cabaletta Bio.
Steven Nichtberger: Co-Founder & CEO of Cabaletta Bio.
Steven Nichtberger: Co-Founder & CEO of Cabaletta Bio.
Contact Info: 1 email address
Michael Milone: Co-Founder of Cabaletta Bio.

View details of Cabaletta Bio's Founder profiles and Board Members

Cabaletta Bio's employee count trend

Cabaletta Bio has 189 employees as of May 26. Here is Cabaletta Bio's employee count trend over the years:

Uncover Cabaletta Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cabaletta Bio include BridgeBio, BeiGene and Alnylam. Here is the list of Top 10 competitors of Cabaletta Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	81/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Abingworth, Blackstone & 13 others	79/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Connecticut Innovations & 9 others	79/100
5th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Arkin & 11 others	78/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
7th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
8th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
9th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
10th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	73/100
35th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Deerfield, University of Pennsylvania & 5 others	66/100